Today: 22 March 2026
Subscribe
Browse Category

NYSE:PLTR 28 January 2026 - 3 February 2026

Salesforce stock price slides nearly 8% as AI disruption fears hit software — what’s next for CRM

Salesforce stock price slides nearly 8% as AI disruption fears hit software — what’s next for CRM

Salesforce shares fell 7.9% to $194.24 Tuesday afternoon, deepening a rout in software stocks as investors questioned whether new AI tools will drive revenue or just add costs. The drop erased $16.57 from Monday’s close and weighed heavily on the Dow. Anthropic’s rollout of a legal plug-in for its Claude chatbot fueled worries about AI disrupting traditional software models.
3 February 2026
······
US economic calendar today: Shutdown scrubs key labor data as Wall Street leans on Fed talk, Treasury plans

US economic calendar today: Shutdown scrubs key labor data as Wall Street leans on Fed talk, Treasury plans

The partial U.S. government shutdown has delayed the January jobs report and December JOLTS data, clearing Tuesday’s economic calendar. S&P 500 and Nasdaq 100 futures rose modestly in premarket trading, while Treasuries slipped. Teradyne and Palantir jumped after strong forecasts. Richmond Fed President Tom Barkin is set to speak at 8 a.m. ET.
3 February 2026
·····
AI stocks today: Nvidia slips as OpenAI shops for chip alternatives, AMD earnings loom

AI stocks today: Nvidia slips as OpenAI shops for chip alternatives, AMD earnings loom

Nvidia fell 2.9% to $185.61 premarket after reports that OpenAI is dissatisfied with some of its latest AI chips and is seeking alternatives. AMD rose 4% to $246.27 ahead of its earnings report, while Palantir and Teradyne gained on positive AI investment news. Super Micro Computer advanced 2.1% before its quarterly results.
3 February 2026
·······
Palantir stock price whipsaws after earnings: PLTR forecast lifts 2026 outlook, then cools

Palantir stock price whipsaws after earnings: PLTR forecast lifts 2026 outlook, then cools

Palantir reported Q4 revenue of $1.41 billion, up 70% year-over-year, and issued 2026 guidance above analyst forecasts. Shares swung between $144 and $161 after hours before settling at $147.76. U.S. commercial revenue jumped 137% to $507 million, while government revenue rose 66% to $570 million. The company posted GAAP operating income of $575 million with a 41% margin.
3 February 2026
··
Palantir Technologies stock pops after earnings as OpenAI chip doubts hit Nvidia — AI stocks in focus

Palantir Technologies stock pops after earnings as OpenAI chip doubts hit Nvidia — AI stocks in focus

Palantir shares jumped 7% after hours Monday as the company forecast 2026 revenue near $7.2 billion and reported U.S. commercial sales up 137% last quarter. Nvidia fell 2.9%, while AMD rose 4%. OpenAI is testing alternatives to Nvidia chips but remains reliant on them for most inference tasks. Snowflake announced a $200 million partnership with OpenAI to integrate its models across major cloud platforms.
2 February 2026
····
Nvidia slips on OpenAI funding doubts while Oracle pops — AI stocks in focus today

Nvidia slips on OpenAI funding doubts while Oracle pops — AI stocks in focus today

Nvidia fell 1.4% to $188.47 after reports of internal doubts over its support for OpenAI, while Oracle jumped 3% to $169.47 on plans to raise up to $50 billion for cloud expansion. AMD gained 4.9% and Palantir rose 2.4% ahead of earnings. Investors are watching for signs of AI demand as major tech firms prepare to report results this week.
2 February 2026
·······
Palantir stock rises ahead of earnings after William Blair upgrade puts $200 back in play

Palantir stock rises ahead of earnings after William Blair upgrade puts $200 back in play

Palantir shares climbed 2.2% to $149.82 Monday morning ahead of quarterly results due after the close. William Blair upgraded the stock, projecting a return above $200 within 12 months and citing strong December quarter signals. The stock remains down about 30% from its record high. Investors await management’s outlook on commercial demand and margins amid volatile AI sector trading.
2 February 2026
··
US economic calendar today: ISM factory PMI ahead as S&P 500 futures slip, oil tumbles

US economic calendar today: ISM factory PMI ahead as S&P 500 futures slip, oil tumbles

S&P 500 futures dropped 0.5% and oil prices plunged 4.9% to $62.05 a barrel in early trading Monday as the U.S. entered a government shutdown. Gold fell 1.8% after CME Group raised margin requirements. Factory and PMI data are due this morning, with Friday’s jobs report in focus. Tesla and NVIDIA shares slipped about 1% premarket, while Oracle rose nearly 4%.
2 February 2026
········
Palantir Technologies co-founder Peter Thiel ditched Nvidia for Apple and Microsoft — here’s what the filings show

Palantir Technologies co-founder Peter Thiel ditched Nvidia for Apple and Microsoft — here’s what the filings show

Thiel Macro LLC reported no Nvidia shares in its latest U.S. stock filing, after holding 537,742 at end-June 2025. The fund listed stakes in Tesla, Apple, and Microsoft as of September 2025, with U.S. equity holdings dropping to $74.4 million from $212 million three months earlier. The portfolio shift is drawing attention as investors reassess AI exposure before Monday’s market open.
1 February 2026
······
Palantir stock price could swing 9% after earnings — what traders watch going into Monday

Palantir stock price could swing 9% after earnings — what traders watch going into Monday

Palantir shares dropped 3.47% Friday to $146.59 ahead of its fourth-quarter earnings report, scheduled for Monday after markets close. Options pricing signals a possible 9% swing in the stock next week. Shares have fallen nearly 30% since November’s record high. Reports of Palantir’s AI being used by U.S. immigration authorities have added to volatility.
31 January 2026
··
1 2 3 4 5 … 12

Stock Market Today

  • Savara (SVRA) Faces Valuation Questions After Share Price Decline
    March 22, 2026, 5:08 PM EDT. Savara (SVRA) shares have declined 3.88% over one day and 23.34% in three months, raising concerns among investors. Despite this, the one-year total shareholder return remains strong at 75.89%. The clinical-stage biotech, focused on rare respiratory diseases, is loss-making with no current revenue. It trades at a price-to-book (P/B) ratio of 6.2x, notably above the US biotech sector average of 2.5x and peer average of 4.5x, signaling potentially rich valuation based on future growth expectations. Investors are cautious as ongoing losses of $118.8 million and key Phase 3 trial outcomes could impact valuation. With limited financial models available, the stock appears overvalued. Market watchers should carefully weigh the high risk and reward profile, while diversifying their portfolios beyond Savara.
Go toTop